All relevant data can be accessed through the use of Oncomine Research Edition (<https://www.oncomine.org/resource/login.html>). All Oncomine dataset titles as well as original article reference are located in S2 Table of the supporting information.

Introduction {#sec001}
============

In the last few decades, cancer has become a focal cause of death worldwide. Until recently, therapeutic methods applied as cancer treatments (primarily surgery, chemotherapy, radiation therapy) had not changed much from 40 years ago. Although different research approaches have been taken to enhance the survival rate and life quality of cancer patients, much effort and many more trials are still needed to accelerate and facilitate cancer treatment.

Ion channels are well documented as novel potential therapeutic targets in cancer treatment due to their integration with many cancer features such as cell proliferation, apoptosis, metastatic capability and migration \[[@pone.0125766.ref001]\]. Calcium (Ca^2+^) is the key player in cell proliferation, activating or inhibiting various intracellular enzymes in numerous compartments including the cytosol, organelles, and nucleus. Intracellular Ca^2+^ levels, through calmodulin, regulate many different kinases, phosphatases, cyclases, esterases and ion channels. A number of mechanisms involving plasma membrane ion channels and ion exchangers associated with the endoplasmic reticulum and nuclear envelope calcium stores control the levels of free Ca^2+^ in the protoplasm \[[@pone.0125766.ref002], [@pone.0125766.ref003]\]. The impact of changes in Ca^2+^ can be specifically determined by the location, extent, duration, and timing of intracellular Ca^2+^ oscillations. For instance, slight variations in Ca^2+^ could regulate specific cell functions, whereas a substantial alteration of Ca^2+^ could be responsible for cell proliferation and motility or even cell apoptosis \[[@pone.0125766.ref004]\].

Calcium channels can be classified into two main types: voltage-gated calcium channels (VGCCs) and ligand-gated calcium channels. The L-type \[[@pone.0125766.ref005], [@pone.0125766.ref006]\], N-Type \[[@pone.0125766.ref007]\], P-type \[[@pone.0125766.ref008]--[@pone.0125766.ref010]\], T-type \[[@pone.0125766.ref011]--[@pone.0125766.ref013]\] and R-type \[[@pone.0125766.ref014], [@pone.0125766.ref015]\] calcium channels that constitute the VGCC family are involved in the development of various types of cancer ([Table 1](#pone.0125766.t001){ref-type="table"}). In addition, ligand-gated calcium channels regulate many processes occurring at the onset of cancer such as activation of the IP3 receptor \[[@pone.0125766.ref016]\] and ryanodine \[[@pone.0125766.ref017]\].

10.1371/journal.pone.0125766.t001

###### Voltage-gated calcium channel localization and functions.

![](pone.0125766.t001){#pone.0125766.t001g}

  Channel            Current   Associated subunits          Expression detected                                                                       General Cellular functions                                             References
  ------------------ --------- ---------------------------- ----------------------------------------------------------------------------------------- ---------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------
  Cav1.1 (CACNA1S)   L         α2δ, β, γ                    Brain, Leukemia                                                                           Excitation-contraction coupling                                        \[[@pone.0125766.ref018]--[@pone.0125766.ref023]\]
  Cav1.2 (CACNA1C)   L         α2δ, β, γ                    Colorectal, Gastric, Pancreas, Sarcoma, Leukemia, Brain, Breast, Uterus, Skin, Prostate   Excitation-contraction coupling                                        \[[@pone.0125766.ref018]--[@pone.0125766.ref023]\]
  Cav1.3 (CACNA1D)   L         α2δ, β, γ                    Prostate, Breast, Colorectal, Bladder, Gastric, Lung, Brain, Uterus, Esophagus            Excitation-contraction coupling                                        \[[@pone.0125766.ref018]--[@pone.0125766.ref023]\]
  Cav1.4 (CACNA1F)   L         α2δ, β, γ                    Testis                                                                                    Excitation-contraction coupling                                        \[[@pone.0125766.ref018]--[@pone.0125766.ref023]\]
  Cav2.1 (CACNA1A)   P/Q       α2δ, β, possibly γ           Leukemia, Ovarian, Sarcoma, Brain, Uterus, Ovarian, Lung, Cervix,                         Neurotransmitter release; dendritic Ca2+ transients; hormone release   \[[@pone.0125766.ref018], [@pone.0125766.ref019], [@pone.0125766.ref024]--[@pone.0125766.ref029]\]
  Cav2.2 (CACNA1B)   N         α2δ/β1, β3, β4, possibly γ   Prostate, Breast                                                                          Neurotransmitter release; dendritic Ca2+ transients; hormone release   \[[@pone.0125766.ref018], [@pone.0125766.ref019], [@pone.0125766.ref028], [@pone.0125766.ref030]--[@pone.0125766.ref033]\]
  Cav2.3 (CACNA1E)   R         α2δ, β, possibly γ           Esophagus, Uterus                                                                         Repetitive firing; dendritic calcium transients                        \[[@pone.0125766.ref018], [@pone.0125766.ref019], [@pone.0125766.ref034]--[@pone.0125766.ref037]\]
  Cav3.1 (CACNA1G)   T         None                         Sarcoma, Colorectal, Uterus, Lung, Prostate, Breast                                       Pacemaking; repetitive firing                                          \[[@pone.0125766.ref018], [@pone.0125766.ref019], [@pone.0125766.ref038]--[@pone.0125766.ref043]\]
  Cav3.2 (CACNA1H)   T         None                         Renal, Sarcoma, Gastric                                                                   Pacemaking; repetitive firing                                          \[[@pone.0125766.ref018], [@pone.0125766.ref019], [@pone.0125766.ref038]--[@pone.0125766.ref043]\]
  Cav3.3 (CACNA1I)   T         None                         Breast, Sarcoma, Esophagus                                                                Pacemaking; repetitive firing                                          \[[@pone.0125766.ref018], [@pone.0125766.ref019], [@pone.0125766.ref038]--[@pone.0125766.ref043]\]

Microarray technology has introduced an experimental approach without bias into sample screening and data collection, leading to the creation of hypotheses \[[@pone.0125766.ref044]\]. Although the data from these analyses need to be confirmed by further detailed studies, it nonetheless helps to somehow foresee the trend of information. Genes are usually considered to represent potential cancer markers when they show differential overexpression in a particular cancer. The existing literature contains thousands of mRNA expression profile studies of various cancers, and a large number of datasets have been made publicly available. The proper and full utilization of this huge resource would therefore accelerate the identification of important cancer markers as well as facilitate the development of improved molecular signatures. A previous study showed that altered gene expression in cancer tissue may play an oncogenic role and promote tumor development; therefore, in the present findings, we focus only on the overexpression of VGCCs in different types of cancer. We hypothesized, based on our bioinformatics screening, that an increase in mRNA expression of VGCCs reflects some degree of participation in cancer progression and development. We have explored potential markers of VGCC overexpression in cancer using the web-based ONCOMINE microarray database \[[@pone.0125766.ref045], [@pone.0125766.ref046]\]. The current investigation focused on the novel regulation of calcium channel family members in different types of cancer, with the supposition that these clinical data would provide important hints that will enable further investigation of the roles of these voltage-gated calcium channels in the progression and development of cancer.

Materials and Methods {#sec002}
=====================

The expression of VGCC mRNA in clinical cancer tissues was analyzed by performing a meta-analysis of public microarray data according to PRISMA guidelines \[[@pone.0125766.ref047], [@pone.0125766.ref048]\] ([S1 Table](#pone.0125766.s001){ref-type="supplementary-material"} and [S1 Fig](#pone.0125766.s001){ref-type="supplementary-material"}). We used the web-based microarray database called ONCOMINE ([www.oncomine.org](http://www.oncomine.org/)) to obtain a systematic analysis of all public cancer microarray data. The website document "ONCOMINE Platform Overview Q1 2014" indicates that this database contains more than 700 independent datasets comprising nearly 90,000 microarray experiments. Most microarray expression analyses define the up and down-expression of genes in nearly every major cancer type as well as in a number of clinical and pathology-based cancer subtypes.

We set threshold criteria to screen potential oncogenes with respect to datasets regulating VGCC transcript expression in cancer tissues \[[@pone.0125766.ref049], [@pone.0125766.ref050]\]. The statistical levels for the screening criteria used in this study were as follows: the fold change must above 1.5, the P-value must be less than 0.05, and the percentile ranking of the gene must be less than 10%. P-values and statistical significance in different types of cancer for differential expression of VGCCs were calculated using the ONCOMINE default algorithms, which included two-tailed Student\'s t-test and multiple testing corrections. In the present report, a P-value \<0.05 indicated a statistically significant difference between samples. We used a fold-change-based benchmark to identify linear model correlation between mRNA levels and VGCC gene expression in cancer tissues relative to normal expression levels in the same tissue section. Only samples with a fold change \>1.5 were chosen for inclusion in the investigative procedure. The degree of expression was determined from the gene rank percentile, which typically classified the genes of interest according to p-values. The top 10% of the altered VGCC genes were used in the analytical process. Ultimately, we retained 50 studies integrating 8174 samples ([S2 Table](#pone.0125766.s002){ref-type="supplementary-material"} and [S1 Fig](#pone.0125766.s001){ref-type="supplementary-material"}).

To present the collected datasets, samples must be reviewed and grouped into logical sample sets. The analysis types are matched cancer/normal tissue and the numerous molecular subtypes, biomarker status, treatment responses, and other miscellaneous comparisons. After the classification of logical analyses, each gene was assessed using different statistical analyses such as Student's t-test and Pearson's correlation depending on how many classes of ordinal analyses were found. These tests were completed using the R statistical computing package ([http://www.r-project.org](http://www.r-project.org/)). Tests were carried out as one-sided or two-sided based on the type of expression analysis. To rationalize the numerous hypothesis assessments, we computed Q values using the following equation: Q = NP / R where P is the P-value, N is the number of genes analyzed, and R is the sorted rank of the P-value \[[@pone.0125766.ref045], [@pone.0125766.ref046]\]. The expression of the gene CACNA1A in ovarian \[[@pone.0125766.ref051]\], breast \[[@pone.0125766.ref052]\], lung \[[@pone.0125766.ref053]\] and gastric cancer was analyzed using the Kaplan-Meier Plotter (<http://kmplot.com/analysis/>) database, which consists of a pool of gene expression and clinical data. Up to the present, this database covers information on 22,277 genes and their influence on survival in 4,142, 1,648, 765 and 2,437 patients with breast, ovarian, gastric and lung cancer, respectively. We focused our analysis on overall survival patient information. There are two groups of patient samples, which are higher and lower expression levels. A Kaplan-Meier survival plot was employed to compare the expression of CACNA1A in those two groups. The hazard ratio with 95% confidence intervals and log rank *p value* was also computed ([S2](#pone.0125766.s002){ref-type="supplementary-material"} and [S3](#pone.0125766.s003){ref-type="supplementary-material"} Figs).

Results and Discussion {#sec003}
======================

1. Voltage-gated calcium channel family promotes cancer development {#sec004}
-------------------------------------------------------------------

The dynamic balance between extracellular and intracellular Ca2+ generally regulates calcium signals \[[@pone.0125766.ref054]\]. This oscillation plays a crucial role in a cell's ability to recommence the cell cycle, to stimulate DNA synthesis at the G1/S transition, and to enter into mitosis during M phase of the cell cycle \[[@pone.0125766.ref004]\]. The potential of the so-called T-type calcium channel subtype to moderate the intracellular Ca2+ level has made this channel a focus for regulation in malignant tumor cells \[[@pone.0125766.ref004]\].

Calcium channels are key players in the cell proliferation process. T-type calcium channels have recently drawn attention as potential therapeutic targets in cancer treatment. A T-type calcium channel inhibitor leads to cell growth inhibition and apoptosis in HCT116 cells \[[@pone.0125766.ref055]\]. It is also well documented that T-type selective properties have anti-proliferative effects in malignant tumor cells \[[@pone.0125766.ref056]\]. T-type channels are well documented to be involved in cell growth and differentiation, to be over-expressed in various stages of tumors, and to participate in calcium-mediated cell growth \[[@pone.0125766.ref055]--[@pone.0125766.ref058]\]. In addition, T-type calcium channels are broadly expressed in different types of cancer and play a key role in cell proliferation \[[@pone.0125766.ref057], [@pone.0125766.ref059]\]. Several calcium channel blockers, such as verapamil \[[@pone.0125766.ref060]\], nifedipine \[[@pone.0125766.ref061]\], TH-1177 \[[@pone.0125766.ref062]\], 2-APB \[[@pone.0125766.ref063]\], and SK&F 96365 \[[@pone.0125766.ref064]\], have been confirmed to inhibit receptor-gated calcium channels, but the particular subtypes of calcium channel have not been investigated. Instead, the involvement of calcium channels in cell growth has been highlighted. We hypothesize that focusing on specific calcium channel subtypes may identify the ones that are controlling the proliferation of different cell types.

Cell migration plays a vital role in various physiological processes such as neural crest cell immigration, leukocyte discharge from the vasculature, and the relocation of fibroblasts during wound healing. Cell migration is also extremely pivotal in metastatic diseases and the development of malignancies. The fundamental mechanism that promotes cell migration is indistinguishable with respect to different cell types. Calcium channel types correlate with various types of cancer, e.g., breast \[[@pone.0125766.ref065]\], prostate \[[@pone.0125766.ref066]\], and ovarian \[[@pone.0125766.ref067]\] cancer. Ca2+ channel activity also triggers oxidative phosphorylation, programmed cell death, and alterations in the apoptosis signaling pathway \[[@pone.0125766.ref068]\].

The P/Q-type, T-type, N-type, R-type, and L type VGCCs all contain the α1 subunit responsible for assembling the calcium-selective pore \[[@pone.0125766.ref041], [@pone.0125766.ref069]\]. This subunit is encoded by various genes spreading from the L-type (CACNA1S, CACNA1C, CACNA1D and CACNA1F) to the T-type (CACNA1G, CACNA1H and CACNA1I) \[[@pone.0125766.ref070]\]. However, to date, no holistic approach has been taken to the screening VGCC family genes in different types of cancer. The present study used a holistic approach to explore VGCC expression in different types of cancer by employing the web-based ONCOMINE microarray database to analyze altered VGCC mRNA expression in 21 types of cancer. We compared the cancer tissue to normal tissue controls and set threshold criteria for screening a suitable dataset from the ONCOMINE database. Inclusion of a suitable dataset for further analysis required that comparisons of gene expression between cancer and normal tissues obeyed specific threshold criteria: the fold change must be above 1.5, the p-value must be less than 0.05, and the gene-ranking percentile must be less than 10%. The fold change, p-value, and the top gene-ranking percentile are presented in [Fig 1](#pone.0125766.g001){ref-type="fig"} for different VGCC genes in different types of cancer tissues.

![Expression of voltage-gated calcium channel (VGCC) genes in different types of cancer.\
Expression of voltage-gated calcium channel (VGCC) genes in 21 types of cancers compared to normal tissue controls. The gene name of each channel is shown. Each gene was found in its tissue of origin, and the color gradient correlates with decreasing gene rank percentile. The search criteria threshold was set at p-value\<0.05 with fold change \>1.5 and gene rank percentile \<10% for screening microarray datasets of cancer versus normal cases.](pone.0125766.g001){#pone.0125766.g001}

2. L-type calcium channel family {#sec005}
================================

The L-type calcium channel genes investigated here include Cav1.1 (CACNA1S), Cav1.2 (CACNA1C), Cav1.3 (CACNA1D), and Cav1.4 (CACNA1F), commonly localized in smooth muscle, skeletal muscle, ventricular myocytes, and bone (osteoblasts). Previous studies on the role of the L-type calcium channel were primarily focused on the physiological and pharmacological aspects \[[@pone.0125766.ref071], [@pone.0125766.ref072]\]; hence, its function is largely unknown in terms of cancer diseases. Our data revealed that CACNA1S was overexpressed relative to normal tissue samples in acute myeloid leukemia (with a 2.42-fold change), in brain desmoplastic medulloblastoma (with a 1.89-fold change), and in primitive neuroectodermal tumors (with a 1.81-fold change) ([Table 2](#pone.0125766.t002){ref-type="table"}). CACNA1S also ranked in the top 5% of upregulated genes in both leukemia and brain cancer ([Fig 1](#pone.0125766.g001){ref-type="fig"}).

10.1371/journal.pone.0125766.t002

###### L-type calcium channel expression in cancer.

![](pone.0125766.t002){#pone.0125766.t002g}

  Gene      Cancer       Subtype                                         N (case)   P-value (Cancer/Normal)   t-Test (Cancer/Normal)   Fold (Cancer/Normal)   \% Gene Ranking     Database References
  --------- ------------ ----------------------------------------------- ---------- ------------------------- ------------------------ ---------------------- ------------------- ---------------------------------------------------------------
  CACNA1S   Brain        Desmoplastic Medulloblastoma                    85         0.002                     3.988                    1.894                  356 (in top 7%)     Nature 2002/01/24\[[@pone.0125766.ref005]\]
                         Primitive Neuroectodermal Tumor, NOS            85         0.015                     2.671                    1.816                  266 (in top 5%)     Nature 2002/01/24\[[@pone.0125766.ref005]\]
            Leukemia     Acute Myeloid Leukemia                          87         0.005                     3.121                    2.427                  578 (in top 5%)     Nat Genet 2004/03/01\[[@pone.0125766.ref006]\]
  CACNA1C   Colorectal   Adenocarcinoma                                  105        7.33E-14                  9.235                    1.642                  214 (in top 2%)     PLoS One 2010/10/01 \[[@pone.0125766.ref073]\]
                         Colon Adenoma                                   64         4.88E-11                  7.974                    4.324                  1145 (in top 6%)    Mol Cancer Res 2007/12/01\[[@pone.0125766.ref074]\]
                         Rectal Adenoma                                  64         2.58E-5                   5.831                    3.795                  1416 (in top 8%)    Mol Cancer Res 2007/12/01\[[@pone.0125766.ref074]\]
            Gastric      Gastrointestinal Stromal Tumor                  90         1.34E-4                   7.113                    2.365                  63 (in top 5%)      Clin Cancer Res 2011/04/01\[[@pone.0125766.ref075]\]
                         Gastric Mixed Adenocarcinoma                    69         4.47E-4                   4.609                    2.222                  1289 (in top 7%)    Eur J Cancer 2009/02/01\[[@pone.0125766.ref076]\]
            Pancreas     Pancreatic Adenocarcinoma                       27         4.07E-4                   4.484                    13.118                 329 (in top 7%)     Cancer Res 2003/05/15\[[@pone.0125766.ref077]\]
            Sarcoma      Synovial Sarcoma                                54         8.15E-4                   3.899                    2.365                  1060 (in top 9%)    Cancer Res 2005/07/01\[[@pone.0125766.ref078]\]
            Leukemia     B-Cell Childhood Acute Lymphoblastic Leukemia   288        0.004                     5.691                    4.155                  769 (in top 7%)     Blood 2011/06/09\[[@pone.0125766.ref079]\]
                         Marginal Zone B-Cell Lymphoma                   27         0.027                     2.449                    1.514                  1254 (in top 9%)    
            Brain        Glioblastoma                                    101        0.006                     5.655                    8.620                  1918 (in top 10%)   Cancer Cell 2006/05/01\[[@pone.0125766.ref080]\]
                         Primitive Neuroectodermal Tumor                 85         0.015                     2.671                    1.816                  47 (in top 9%)      Nature 2002/01/24 \[[@pone.0125766.ref005]\]
                         Oligodendroglioma                               54         0.020                     2.665                    2.651                  1342 (in top 10%)   Cancer Res 2005/10/01\[[@pone.0125766.ref081]\]
            Breast       Breast Phyllodes Tumor                          2136       0.009                     3.731                    1.529                  1310 (in top 7%)    Nature 2012/04/18\[[@pone.0125766.ref082]\]
                         Invasive Lobular Breast Carcinoma               30         0.025                     2.142                    1.901                  943 (in top 5%)     BMC Cancer 2007/03/27\[[@pone.0125766.ref083]\]
            Uterus       Uterine Corpus Leiomyosarcoma                   24         0.017                     2.430                    1.509                  10 (in top 10%)     Genes Chromosomes Cancer 2004/06/01\[[@pone.0125766.ref084]\]
            Skin         Skin Squamous Cell Carcinoma                    15         0.018                     2.673                    2.767                  1050 (in top 9%)    Mol Cancer 2006/08/08 \[[@pone.0125766.ref085]\]
            Prostate     Prostate Carcinoma                              35         0.024                     2.671                    1.622                  670 (in top 8%)     Cancer Res 2002/08/01\[[@pone.0125766.ref086]\]
  CACNA1D   Prostate     Carcinoma                                       112        3.31E-11                  7.543                    2.138                  113 (in top 2%)     PNAS 2004/01/20 \[[@pone.0125766.ref087]\]
                         Carcinoma                                       122        4.17E-10                  6.929                    2.626                  133 (in top 1%)     Nature 2012/05/20 \[[@pone.0125766.ref007]\]
                         Carcinoma                                       185        5.13E-10                  6.873                    1.828                  111 (in top 1%)     Cancer Cell 2010/07/13\[[@pone.0125766.ref088]\]
                         Prostate Carcinoma Epithelia                    101        7.70E-8                   6.104                    5.972                  46 (in top 1%)      Nat Genet 2007/01/01\[[@pone.0125766.ref089]\]
                         Prostatic Intraepithelial Neoplasia Epithelia   101        0.003                     3.131                    4.682                  1060 (in top 10%)   Nat Genet 2007/01/01\[[@pone.0125766.ref089]\]
                         Adenocarcinoma                                  40         2.42E-6                   5.453                    2.199                  176 (in top 1%)     Cancer Res 2003/07/15\[[@pone.0125766.ref090]\]
                         Carcinoma                                       57         1.53E-5                   4.566                    1.747                  1 (in top 1%)       Cancer Res 2006/04/15\[[@pone.0125766.ref091]\]
                         Carcinoma                                       21         2.57E-5                   5.486                    4.061                  49 (in top 1%)      Clin Cancer Res 2009/09/15\[[@pone.0125766.ref092]\]
                         Adenocarcinoma                                  89         3.57E-4                   3.760                    2.059                  393 (in top 4%)     Cancer Res 2008/02/01\[[@pone.0125766.ref093]\]
                         Carcinoma                                       30         0.002                     3.439                    6.348                  127 (in top 1%)     Mol Carcinog 2002/01/01\[[@pone.0125766.ref094]\]
                         Carcinoma                                       15         0.015                     2.701                    17.129                 197 (in top 4%)     Cancer Res 2001/08/01\[[@pone.0125766.ref095]\]
            Breast       Invasive Lobular Breast Carcinoma               593        2.52E-10                  7.399                    3.431                  1031 (in top 6%)    TCGA
                         Mixed Lobular and Ductal Breast Carcinoma       593        1.35E-4                   6.197                    4.200                  914 (in top 5%)     TCGA
                         Invasive Ductal and Lobular Carcinoma           593        0.002                     8.208                    4.839                  1474 (in top 8%)    TCGA
                         Invasive Mixed Breast Carcinoma                 63         0.011                     2.804                    4.365                  708 (in top 5%)     PNAS 2005/08/02 \[[@pone.0125766.ref096]\]
                         Invasive Ductal Breast Carcinoma                63         0.021                     2.354                    2.991                  1157 (in top 7%)    PNAS 2005/08/02 \[[@pone.0125766.ref096]\]
                         Invasive Lobular Breast Carcinoma               63         0.025                     2.222                    2.996                  1025 (in top 7%)    PNAS 2005/08/02 \[[@pone.0125766.ref096]\]
            Colorectal   Adenocarcinoma                                  105        2.45E-8                   6.148                    1.527                  1089 (in top 6%)    PLoS One 2010/10/01\[[@pone.0125766.ref073]\]
                         Adenoma                                         105        1.32E-5                   6.949                    3.577                  1150 (in top 6%)    PLoS One 2010/10/01\[[@pone.0125766.ref073]\]
                         Rectosigmoid Adenocarcinoma                     237        1.68E-5                   5.628                    1.788                  663 (in top 4%)     TCGA
            Bladder      Superficial Bladder Cancer                      60         4.49E-6                   5.087                    2.114                  1089 (in top 9%)    Cancer Res 2004/06/01\[[@pone.0125766.ref097]\]
            Gastric      Gastric Mixed Adenocarcinoma                    69         1.13E-4                   5.235                    3.467                  856 (in top 5%)     Eur J Cancer 2009/02/01\[[@pone.0125766.ref076]\]
                         Gastric Cancer                                  160        7.45E-4                   3.246                    1.519                  1058 (in top 6%)    Nucleic Acids Res 2011/03/01\[[@pone.0125766.ref098]\]
            Lung         Lung Carcinoid Tumor                            203        2.50E-4                   4.121                    3.611                  396 (in top 5%)     PNAS 2001/11/20\[[@pone.0125766.ref099]\]
            Brain        Glioblastoma                                    101        3.85E-4                   6.345                    3.293                  1069 (in top 6%)    Cancer Cell 2006/05/01\[[@pone.0125766.ref080]\]
            Uterus       Uterine Corpus Leiomyoma                        77         5.44E-4                   3.496                    2.143                  1492 (in top 8%)    Cancer Res 2009/08/01 \[[@pone.0125766.ref014]\]
            Esophagus    Adenocarcinoma                                  48         6.66E-4                   4.155                    2.447                  318 (in top 9%)     Gastroenterology 2006/09/01\[[@pone.0125766.ref015]\]
                         Barrett\'s Esophagus                            48         0.002                     3.242                    2.123                  1158 (in top 8%)    Gastroenterology 2006/09/01\[[@pone.0125766.ref015]\]
  CACNA1F   Testis       Testicular Teratoma                             30         0.018                     2.859                    1.896                  829 (in top 6%)     Cancer Res 2005/07/01\[[@pone.0125766.ref078]\]

Previous research showed that CACNA1C could cause pathophysiology of psychiatric disease \[[@pone.0125766.ref100]\], and CACNA1C has high transcript activity in the prostate stroma \[[@pone.0125766.ref101]\]. We found high CACNA1C expression in prostate carcinoma in comparison to normal tissue in the Cancer research 2002/08/01 \[[@pone.0125766.ref086]\] database ([Table 2](#pone.0125766.t002){ref-type="table"}). These data are consistent with those of a previous study \[[@pone.0125766.ref101]\]. We also found high expression of CACNA1C in most cancer types, including colorectal, gastric, pancreas, brain, breast, uterus, skin, and prostate cancers and leukemia ([Table 2](#pone.0125766.t002){ref-type="table"}). We further found that 10 out of 21 different tumor tissues showed upregulation, with CACNA1C appearing in the top 10% of the most augmented genes ([Fig 1](#pone.0125766.g001){ref-type="fig"}). For example, colorectal cancers such as colon adenoma, adenocarcinoma, and rectal adenoma showed significant upregulation of CACNA1C when compared to normal control tissues, with p-values ranging from 2.58E-5 to 7.33E-14 and CACNA1C ranking from 2% to 8%. CACNA1C expression was also elevated in pancreatic carcinoma compared to normal tissue, with a 13.118-fold increase, a p-value of 4.07E-4, and gene ranking at 7%.

CACNA1D is believed to regulate cell firing \[[@pone.0125766.ref102]\] and has a high correlation with prostate cancer \[[@pone.0125766.ref017]\]; however, its expression in other cancer types is still largely unstudied. Our bioinformatics analysis verified that CACNA1D was highly expressed in most types of cancer, including prostate and breast cancer ([Table 2](#pone.0125766.t002){ref-type="table"}). These data are consistent with the findings of a previous study \[[@pone.0125766.ref017]\]. We also found that 9 of the 21 tissue sections from cancer patients showed overexpression, with CACNA1D categorized in the top 10% of the most elevated genes ([Fig 1](#pone.0125766.g001){ref-type="fig"}). Prostate cancers such as prostate carcinoma, intraepithelial neoplasia, and adenocarcinoma all showed dramatic overexpression of CACNA1D relative to normal tissues. Upregulation ranged from 1.747- to 17.129-fold in terms of CACNA1D transcript expression, with p-values ranging from 0.015 to 3.31E-11 and gene rankings ranging from the top 1% to the top 4%. Breast cancers such as invasive lobular breast carcinoma, invasive ductal and lobular carcinoma, mixed lobular and ductal breast carcinoma, and invasive mixed breast carcinoma all exhibited substantial overexpression of CACNA1D relative to control samples. Upregulation ranged from 2.99- to 4.84-fold in terms of CACNA1D transcript expression, with p-values ranging from 0.025 to 2.52E-10 and gene rankings ranging from the top 5% to the top 7%. A particularly novel finding was that CACNA1D was highly expressed in prostate cancer but also in breast, colorectal, bladder, gastric, lung, brain, uterine, and esophageal tumors. Our *in silico* analysis suggests that CACNA1D may be a novel oncogene in cancer development, but further experiments are needed to explore the details of the role of CACNA1D in cancer progression.

A larger role in human physiology beyond its function in photoreceptors was suggested for CACNA1F \[[@pone.0125766.ref102]\]; however, the role of CACNA1F in cancer remains obscure. Only one study satisfied the selection benchmark with a 1.89-fold change in CACNA1F expression in testicular teratoma \[[@pone.0125766.ref103]\], wherein CACNA1F ranked in the top 6% of testicular teratoma gene changes and the p-value was 0.018 ([Table 2](#pone.0125766.t002){ref-type="table"}).

3. P/Q-type calcium channel family {#sec006}
----------------------------------

Cav2.1 (CACNA1A) is the only gene belonging to the P/Q-type calcium channel family, and it is often localized in Purkinje cells or cerebellar granule cells. This channel plays roles in neurotransmission and dendritic calcium transients \[[@pone.0125766.ref019]\]. P-type and Q-type currents are different in location. P-type are located in the Purkinje neurons of the cerebellum whereas Q-Type have been identified in cerebellar granule neurons \[[@pone.0125766.ref104], [@pone.0125766.ref105]\]. Both types of currents are produced by ion channels encoded by the calcium channel, voltage-dependent, P/Q type, alpha 1A subunit (CACNA1A) gene. They are phenotypically distinguished by an RNA splicing variation \[[@pone.0125766.ref106], [@pone.0125766.ref107]\]. Different mutations in alpha subunit 1A lead to certain neuronal degradation diseases such as episodic ataxia type-2, familial hemiplegic migraine and spinocerebellar ataxia type-6 \[[@pone.0125766.ref108]--[@pone.0125766.ref112]\]. In the present study, we found that CACNA1A was highly expressed in most cancers, including leukemia and ovarian cancer ([Table 3](#pone.0125766.t003){ref-type="table"}). We also found that 7 out of 21 cancer tissues showed high expression of CACNA1A, and it was categorized in the top 10% of the most increased genes ([Fig 1](#pone.0125766.g001){ref-type="fig"}). Leukemias such as chronic lymphocytic leukemia, monoclonal gammopathy of undetermined significance, skin squamous cell carcinoma, and marginal zone b-cell lymphoma all presented significant overexpression of CACNA1A relative to control samples. The *in silico* analysis showed increased expression ranging from 1.77- to 2.27-fold for CACNA1A with p-values ranging from 0.003 to 3.56E-80 and gene rankings ranging from the top 2% to 5%. Lung carcinoma cells showed the most significant increases in expression relative to control samples with 15.568-fold up-regulation, a p-value of 0.001, and a gene ranking in the top 4%. Overall, our bioinformatics analysis indicated that CACNA1A may be a potential therapeutic target for leukemia, lung, ovarian, brain, uterine, and cervical cancers.

10.1371/journal.pone.0125766.t003

###### P-type calcium channel expression in cancer.
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  Gene      Cancer     Subtype                                                            N (case)   P-value (Cancer/Normal)   t-Test (Cancer/Normal)   Fold (Cancer/Normal)   \% Gene Ranking    Database References
  --------- ---------- ------------------------------------------------------------------ ---------- ------------------------- ------------------------ ---------------------- ------------------ ---------------------------------------------------------
  CACNA1A   Leukemia   Chronic Lymphocytic Leukemia                                       2096       3.56E-80                  23.560                   1.765                  232 (in top 2%)    J Clin Oncol 2010/05/20 \[[@pone.0125766.ref114]\]
                       Monoclonal Gammopathy of Undetermined Significance                 78         1.33E-6                   5.258                    2.053                  767 (in top 4%)    Blood 2007/02/15 \[[@pone.0125766.ref115]\]
                       Skin Squamous Cell Carcinoma                                       87         2.31E-4                   4.688                    3.389                  35 (in top 5%)     BMC Med Genomics 2008/04/28 \[[@pone.0125766.ref116]\]
                       Marginal Zone B-Cell Lymphoma                                      27         0.003                     3.787                    2.271                  189 (in top 2%)    J Invest Dermatol 2003/05/01 \[[@pone.0125766.ref008]\]
            Ovarian    Carcinoma                                                          195        5.20E-8                   8.750                    1.758                  1087 (in top 9%)   Cancer Res 2008/07/01 \[[@pone.0125766.ref009]\]
            Sarcoma    Myxoid/Round Cell Liposarcoma                                      158        8.07E-8                   7.026                    1.711                  905 (in top 8%)    Nat Genet 2010/07/04 \[[@pone.0125766.ref010]\]
                       Dedifferentiated Liposarcoma                                       158        1.86E-7                   5.847                    1.575                  706 (in top 6%)    Nat Genet 2010/07/04 \[[@pone.0125766.ref010]\]
                       Synovial Sarcoma                                                   54         2.38E-4                   4.461                    4.470                  712 (in top 6%)    Cancer Res 2005/07/01 \[[@pone.0125766.ref078]\]
            Brain      Classic Medulloblastoma                                            85         5.24E-6                   4.935                    6.574                  305 (in top 6%)    Nature 2002/01/24 \[[@pone.0125766.ref005]\]
                       Primitive Neuroectodermal Tumor, NOS                               85         0.015                     2.671                    1.816                  390 (in top 8%)    Nature 2002/01/24 \[[@pone.0125766.ref005]\]
                       Glioblastoma                                                       101        6.67E-6                   6.947                    5.843                  550 (in top 3%)    Cancer Cell 2006/05/01 \[[@pone.0125766.ref080]\]
            Uterus     Uterine Corpus Leiomyoma                                           77         1.22E-5                   4.578                    2.687                  602 (in top 4%)    Cancer Res 2009/08/01 \[[@pone.0125766.ref014]\]
            Ovaria     Ovarian Serous Cystadenocarcinoma                                  594        1.47E-5                   8.013                    2.563                  1077 (in top 9%)   TCGA
            Lung       Lung Carcinoid Tumor                                               203        2.26E-5                   4.656                    6.098                  222 (in top 3%)    PNAS 2001/11/20 \[[@pone.0125766.ref099]\]
                       Small Cell Lung Carcinoma                                          203        0.001                     4.583                    15.568                 320 (in top 4%)    PNAS 2001/11/20 \[[@pone.0125766.ref099]\]
            Cervix     High Grade Cervical Squamous Intraepithelial Neoplasia Epithelia   41         0.004                     3.541                    1.601                  873 (in top 7%)    Cancer Res 2007/11/01 \[[@pone.0125766.ref117]\]

When applying Kaplan-Meier plotter analysis, correlations between the overexpression of CACNA1A and overall lower survival rates in lung cancer \[[@pone.0125766.ref053]\] and ovarian cancer ([S2 Fig](#pone.0125766.s002){ref-type="supplementary-material"}) were shown by using the GSE9891 database \[[@pone.0125766.ref051], [@pone.0125766.ref113]\]. This result is consistent with our data in [Table 3](#pone.0125766.t003){ref-type="table"}. The high expression of CACNA1A shows that this gene is possibly involved in the onset and progression of lung and ovarian cancer (poor prognosis). In contrast, an opposite trend was observed in breast and stage IV gastric cancer with low expression of CACNA1A \[[@pone.0125766.ref052]\]. These data show consistency with [Fig 1](#pone.0125766.g001){ref-type="fig"}. In other words, CACNA1A was down-regulated in breast and gastric cancer ([S3 Fig](#pone.0125766.s003){ref-type="supplementary-material"}). These studies showed that CACNA1 expression plays an essential role in the progression of ovarian and lung cancer.

4. N-type calcium channel family {#sec007}
--------------------------------

The N-type calcium channel family contains only Cav2.2 (CACNA1B), which is located throughout the brain and peripheral nervous system. Previous studies have shown that CACNA1B is important for sustained neuronal firing and neurotransmitter release in neuropathic pain \[[@pone.0125766.ref025], [@pone.0125766.ref029]\]; however, until now, CACNA1B has not been implicated in cancer. Our bioinformatics results indicated thatCACNA1B was among the top 9% and top 6% of overexpressed genes in prostate and breast cancer, respectively. In these cancers, increases in CACNA1B expression ranged from 1.53- to 1.56-fold, with p-values from 3.25E-4 to 6.22E-4 relative to control samples ([Table 4](#pone.0125766.t004){ref-type="table"}). Our data suggest that CACNA1B has high expression specifically in clinical prostate and breast cancer tissues. Identification of the underlying role of CACNA1B in cancer development may also help in the discovery of new therapeutic targets for the treatment of prostate and breast cancer.

10.1371/journal.pone.0125766.t004

###### N-type calcium channel expression in cancer.
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  Gene      Cancer     Subtype                                        N (case)   P-value (Cancer/Normal)   t-Test (Cancer/Normal)   Fold (Cancer/Normal)   \% Gene Ranking    Database References
  --------- ---------- ---------------------------------------------- ---------- ------------------------- ------------------------ ---------------------- ------------------ ----------------------------------------------
  CACNA1B   Prostate   Carcinoma                                      122        3.25E-4                   3.624                    1.532                  1710 (in top 9%)   Nature 2012/05/20 \[[@pone.0125766.ref007]\]
            Breast     Intraductal Cribriform Breast Adenocarcinoma   593        6.22E-4                   3.418                    1.564                  1032 (in top 6%)   TCGA

5. T-type calcium channel family {#sec008}
--------------------------------

Cav3.1 (CACNA1G), Cav3.2 (CACNA1H), and Cav3.3 (CACNA1I) are all classified into the T-type calcium channel family, which is localized in neuronal cells, pacemaker cells and osteocytes (mature bone cells). In addition, another study using ONCOMINE showed that the expression of T-type channel isoforms in an array of malignant tumor cells was significantly elevated relative to surrounding normal tissue \[[@pone.0125766.ref118]\]. This outcome is consistent with the present findings ([Table 5](#pone.0125766.t005){ref-type="table"}). Increased expression of CACNA1G was detected in a broad range of cancer diseases, with CACNA1G in the top 1% of overexpressed genes in synovial sarcoma and in the top 2% in prostate carcinoma. The fold changes ranged from 1.737 to 6.376 and the p-values from 8.70E-4 to 1.71E-7 ([Table 5](#pone.0125766.t005){ref-type="table"}). High expression of CACNA1G was also noted in other tumor types such as colorectal, uterine, prostate, and breast cancer.

10.1371/journal.pone.0125766.t005

###### T-type calcium channel expression in cancer.
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  Gene      Cancer       Subtype                                     N (case)   P-value (Cancer/Normal)   t-Test (Cancer/Normal)   Fold (Cancer/Normal)   \% Gene Ranking    Database References
  --------- ------------ ------------------------------------------- ---------- ------------------------- ------------------------ ---------------------- ------------------ -------------------------------------------------------
  CACNA1G   Sarcoma      Synovial Sarcoma                            54         1.71E-7                   9.065                    6.376                  42 (in top 1%)     Cancer Res 2005/07/01 \[[@pone.0125766.ref011]\]
                         Dedifferentiated Liposarcoma                54         0.002                     3.374                    1.850                  332 (in top 3%)    Cancer Res 2005/07/01 \[[@pone.0125766.ref011]\]
            Colorectal   Rectosigmoid Adenocarcinoma                 237        3.72E-6                   5.749                    1.866                  516 (in top 3%)    TCGA
            Uterus       Uterine Corpus Leiomyoma                    77         4.21E-5                   4.279                    1.743                  796 (in top 5%)    Cancer Res 2009/08/01 \[[@pone.0125766.ref014]\]
            Lung         Adenocarcinoma                              66         7.72E-4                   3.334                    1.956                  215 (in top 10%)   BMC Genomics 2007/06/01 \[[@pone.0125766.ref119]\]
            Prostate     Carcinoma                                   19         8.70E-4                   4.132                    1.737                  302 (in top 2%)    Cancer Cell 2005/11/01 \[[@pone.0125766.ref120]\]
            Breast       Invasive Lobular Breast Carcinoma           30         0.042                     1.908                    2.007                  1533 (in top 8%)   BMC Cancer 2007/03/27 \[[@pone.0125766.ref083]\]
  CACNA1H   Renal        Clear Cell Sarcoma of the Kidney            35         1.51E-6                   7.591                    5.193                  112 (in top 1%)    Clin Cancer Res 2005/11/15 \[[@pone.0125766.ref012]\]
                         Renal Wilms Tumor                           35         0.005                     3.566                    1.704                  808 (in top 7%)    Clin Cancer Res 2005/11/15 \[[@pone.0125766.ref012]\]
            Sarcoma      Synovial Sarcoma                            54         5.68E-4                   4.402                    6.103                  940 (in top 8%)    Cancer Res 2005/07/01 \[[@pone.0125766.ref078]\]
            Gastric      Gastrointestinal Stromal Tumor              90         5.69E-4                   6.075                    9.290                  1509 (in top 8%)   Clin Cancer Res 2011/04/01 \[[@pone.0125766.ref075]\]
  CACNA1I   Breast       Invasive Breast Carcinoma Stroma            59         3.04E-16                  15.313                   2.348                  758 (in top 4%)    Nat Med 2008/05/01 \[[@pone.0125766.ref013]\]
                         Ductal Breast Carcinoma in Situ Epithelia   66         0.002                     3.748                    1.566                  1241 (in top 7%)   Breast Cancer Res 2009/02/02
            Sarcoma      Myxoid/Round Cell Liposarcoma               158        9.11E-9                   7.885                    1.899                  628 (in top 5%)    Nat Genet 2010/07/04 \[[@pone.0125766.ref010]\]
            Esophagus    Esophageal Adenocarcinoma                   48         3.43E-4                   5.451                    2.436                  1014 (in top 7%)   Gastroenerology 2006/09/01\[[@pone.0125766.ref015]\]

CACNA1H showed altered expression in renal cancer, sarcoma, and gastrointestinal stromal tumors ([Fig 1](#pone.0125766.g001){ref-type="fig"}). CACNA1H was located in the top 1% of overexpressed genes in clear cell sarcoma of the kidney and in the top 8% of upregulated genes in synovial sarcoma and gastrointestinal stromal tumors. Compared to normal tissue, the fold change ranged from 5.19 to 9.29 and p-values ranged from 1.51E-6 to 0.005.

CACNA1I showed altered expression in invasive breast cancer, myxoid/round cell liposarcoma, and esophageal adenocarcinoma ([Fig 1](#pone.0125766.g001){ref-type="fig"}). CACNA1I was found in the top 4% to 7% of upregulated genes in invasive breast carcinoma stroma and ductal breast carcinoma *in situ* epithelia, with p-values of 3.04E-16 and 0.002 and fold changes ranging from 1.586 to 2.35, respectively. High expression of CACNA1I was also found in sarcoma and esophageal cancer ([Table 5](#pone.0125766.t005){ref-type="table"}).

T-type calcium channels have recently drawn the attention of researchers as potential therapeutic targets in cancer treatment. T-type channels are well documented to be involved in cell growth and differentiation, to be re-expressed in various tumor phases, and to be involved in calcium-mediated cell death. T-type calcium channels are highly expressed in most types of cancer \[[@pone.0125766.ref121], [@pone.0125766.ref122]\]. Therefore, the development of a specific inhibitor or antagonist drug may serve as a potential approach to treating cancer.

6. R-type calcium channel family {#sec009}
--------------------------------

The R-type calcium channel family contains only Cav2.3 (CACNA1E), which is most often found in cerebellar granule cells and other neurons. CACNA1E was among the top 6% and top 10% of genes overexpressed in esophageal and uterine cancers, respectively. In those cancers, CACNA1E expression increases ranged from 2.09- to 9.19-fold, with p-values from 1.91E-4 to 0.001 relative to the control samples ([Table 6](#pone.0125766.t006){ref-type="table"}). Hence, CACNA1E may also serve as a novel therapeutic target for esophageal and uterine cancers.

10.1371/journal.pone.0125766.t006

###### R-type calcium channel expression in cancer.
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  Gene      Cancer      Subtype                    N (case)   P-value (Cancer/Normal)   t-Test (Cancer/Normal)   Fold (Cancer/Normal)   \% Gene Ranking     Database References
  --------- ----------- -------------------------- ---------- ------------------------- ------------------------ ---------------------- ------------------- -------------------------------------------------------
  CACNA1E   Esophagus   Adenocarcinoma             48         1.91E-4                   5.855                    9.193                  829 (in top 6%)     Gastroenterology 2006/09/01\[[@pone.0125766.ref015]\]
            Uterus      Uterine Corpus Leiomyoma   77         0.001                     3.148                    2.095                  1901 (in top 10%)   Cancer Res 2009/08/01 \[[@pone.0125766.ref014]\]

7. VGCCs and their relationship to metastatic cancer {#sec010}
----------------------------------------------------

Cancer cells are able to metastasize or spread to other tissues or organs during tumor growth \[[@pone.0125766.ref123]\]. As the original tumor progresses through angiogenesis \[[@pone.0125766.ref124]\], it supposedly promotes the circulation of cancerous cells in the peripheral blood system \[[@pone.0125766.ref125]\] or lymphatic system \[[@pone.0125766.ref126]\] and their migration to other tissues or organs \[[@pone.0125766.ref127]\]. These cells then begin growing in the host organs. However, these metastatic growths are not easy to detect and often lead to the death of the patient. Gene expression profiling of human primary breast tumors can predict metastasis risk, and metastatic cancer is also often correlated with poor prognosis \[[@pone.0125766.ref128]\]. Therefore, understanding the association between VGCCs and metastatic cancer represents an important facet of cancer research. However, the correlation between VGCCs and metastatic cancer remains obscure. Hence, exploration of the VGCC gene expression profiles in clinical cancer patients may be useful for predicting metastasis risk.

Invasive lobular breast carcinoma has been frequently found to metastasize to the gastrointestinal tract, peritoneum, retroperitoneum, and gynecological organs \[[@pone.0125766.ref129]--[@pone.0125766.ref131]\]. The BMC Cancer database \[[@pone.0125766.ref083]\] revealed CACNA1C expression in invasive lobular breast carcinoma/normal tissue with a 1.9-fold change ([Table 2](#pone.0125766.t002){ref-type="table"}); thus, we speculated that patients with invasive lobular breast carcinoma with high expression of CACNA1C relative to normal tissue were at risk for metastasis to the gastrointestinal tract, peritoneum, retroperitoneum, and gynecological organs.

The TCGA and PNAS databases \[[@pone.0125766.ref096]\] indicated that CACNA1D was significantly overexpressed relative to normal tissue in invasive lobular breast carcinoma with invasive ductal and lobular carcinoma ([Table 2](#pone.0125766.t002){ref-type="table"}), which again implies that patients with high expression of CACNA1D were likely to develop those diseases.

The BMC Cancer database \[[@pone.0125766.ref083]\] revealed that CACNA1G expression in invasive lobular breast carcinoma samples underwent a 2.0-fold change relative to normal samples ([Table 5](#pone.0125766.t005){ref-type="table"}). This also implies that patients with CACNA1G overexpression relative to normal tissue were likely to experience gastrointestinal tract, peritoneum, retroperitoneum, or gynecological organ transfer. In addition, abundant expression of JMJD2C was noted in invasive breast carcinoma stroma, which would also lead to metastatic disease \[[@pone.0125766.ref132]\]. The Nat Med database \[[@pone.0125766.ref013]\] showed a 2.3-fold change in CACNA1I in invasive breast carcinoma stroma, again implying that patients with high CACNA1G expression would likely develop cancer.

Most types of cancer, including blood cancers and lymphatic system cancers (i.e., leukemia, multiple myeloma, and lymphoma), are able to bring about metastatic tumors. Although rare, blood and lymphatic system cancers have been reported to metastasize to other organs such as the lungs, heart, central nervous system, and other tissues \[[@pone.0125766.ref133]--[@pone.0125766.ref136]\]. Cardiac metastases were found in 53 out of 247 necropsied patients with leukemia or lymphoma \[[@pone.0125766.ref137]\]. The Nat Genet database indicated that L-type calcium channels, such as CACNA1S, were overexpressed in leukemia/normal tissue with a 2.42-fold change \[[@pone.0125766.ref006]\] ([Table 2](#pone.0125766.t002){ref-type="table"}). The Blood database indicated high expression of CACNA1C in leukemia relative to normal samples \[[@pone.0125766.ref079]\] ([Table 2](#pone.0125766.t002){ref-type="table"}). We also found that the P-type CACNA1A calcium channel gene was highly expressed in leukemia compared to normal samples \[[@pone.0125766.ref008], [@pone.0125766.ref009], [@pone.0125766.ref115], [@pone.0125766.ref116]\] ([Table 3](#pone.0125766.t003){ref-type="table"}). Thus, we speculated that leukemia patients with high expression of CACNA1S, CACNA1C, or CACNA1A relative to normal samples are likely to experience metastasis of the cancer cells to the lungs, heart, central nervous system, and other tissues.

8. Voltage-gated calcium channels in clinical applications {#sec011}
----------------------------------------------------------

*In silico* bioinformatics analysis is playing an important role in linking cancer gene expression profiling with potential clinical cancer markers. This type of systematic analysis provides a holistic global view of the clinical data for VGCC gene family expression in various types of cancer diseases, and it also confirmed that expression of VGCC genes may change greatly in metastatic diseases. One interesting feature was that various types of VGCC genes appear to take part in diverse types of cancer. For instance, breast cancer showed dramatic upregulation of CACNA1C, CACNA1D, CACNA1B, CACNA1G, and CACNA1I \[[@pone.0125766.ref013], [@pone.0125766.ref082], [@pone.0125766.ref083], [@pone.0125766.ref096], [@pone.0125766.ref138]\]. Likewise, brain and CNS tumors showed significantly increased expression of CACNA1S, CACNA1C, CACNA1D, and CACNA1A \[[@pone.0125766.ref005], [@pone.0125766.ref080]\]. Our results indicate that CACNA1F is highly expressed only in testis cancer and that CACNA1B is up-regulated only in breast cancer.

Our approach to bioinformatics analysis also utilized the integration and validation of multiple microarray datasets so that the most novel voltage-gated calcium channel markers could be identified for further investigation. Identifying novel VGCC targets and classifying different subtypes of cancers on the basis of DNA microarray data may promote the development of new cancer therapy drugs.

Recently, overexpression of the L-type CACNA1D calcium channel gene was confirmed in prostate cancer \[[@pone.0125766.ref139]\]. In the current research, the CACNA1 family was found to be highly expressed in several varieties of cancer including breast, bladder, colorectal, lung, esophageal, brain and CNS, uterine, and gastric cancers. The finding of an association between colorectal cancer and CACNA1D strongly suggests a new direction for cancer diagnosis and treatment. CACNA1D was found to be expressed in colorectal cancer in the 6th percentile in terms of gene ranking (from the 1st to 10th percentile).

Some studies on calcium channel blockers have been conducted to identify potential targets for cancer suppression \[[@pone.0125766.ref140], [@pone.0125766.ref141]\]. Ligand-gated calcium channels have also been identified as potential therapeutic targets apart from VGCCs. A recent study indicated an association between oncogenic K-Ras IP3-dependent suppression and a calcium release mechanism that strongly suggests a role for IP3 in the function of ligand-gated calcium channels involved in colorectal cancer \[[@pone.0125766.ref142]\].

In conclusion, the current findings show the overexpression of calcium channels in a number of cancer diseases. The overexpression of many calcium channel subunits in cancers shows that they are likely involved in the development of various types of cancer. The observation of overexpression of CACNA1A, CACNA1C, and CACNA1D could make them likely targets in cancer treatment, as it suggests that blockage or partial inhibition of their expression could help to modulate the status of metastatic diseases. However, further detailed investigations on the mechanism of how calcium channel subunits play roles in cancer onset and progression need to be conducted. The present study could serve as a tool for cancer diagnostics and assist in the search more applicable and specific types of cancer treatments.

Supporting Information {#sec012}
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###### Flow chart presenting the identification and collection of the studies for the statistical meta-analysis.

(TIF)

###### 

Click here for additional data file.

###### The CACNA1A gene in breast, gastric, ovarian and lung cancer (Kaplan-Meier Plotter).

Kaplan-Meier plots showing overall survival in breast, gastric, ovarian and lung cancer. Over-expression of CACNA1A in ovarian and lung cancer would cause poor prognosis, whereas in breast and gastric it would lead to good prognosis. Breast cancer, p = 1.4X 10--7; gastric cancer, p = 0.038; ovarian cancer, p = 0.001; lung cancer, p = 2.4 X10-5.

(TIF)
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Click here for additional data file.

###### CACNA1A gene analysis in breast, gastric, ovarian and lung cancer (ONCOMINE database).

Box plots derived from gene expression data in ONCOMINE comparing expression of the CACNA1A gene in normal (left plot) and various types of cancer tissue (right plot).

(TIF)
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###### ONCOMINE dataset reference list.
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